221 related articles for article (PubMed ID: 36413432)
21. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
[TBL] [Abstract][Full Text] [Related]
22. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
23. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
Matsuno O; Minamoto S
Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
[TBL] [Abstract][Full Text] [Related]
24. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
25. The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion.
Milne ME; Kimball J; Tarrant TK; Al-Rohil RN; Leverenz DL
Curr Allergy Asthma Rep; 2022 Nov; 22(11):141-150. PubMed ID: 36103081
[TBL] [Abstract][Full Text] [Related]
26. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
27. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Pagnoux C; Groh M
Expert Rev Clin Immunol; 2016 Oct; 12(10):1059-67. PubMed ID: 27191665
[TBL] [Abstract][Full Text] [Related]
28. [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].
Hellmich B; Holle J; Moosig F
Z Rheumatol; 2022 May; 81(4):286-299. PubMed ID: 35075511
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
30. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
31. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
32. Update on eosinophilic granulomatosis with polyangiitis.
Furuta S; Iwamoto T; Nakajima H
Allergol Int; 2019 Oct; 68(4):430-436. PubMed ID: 31266709
[TBL] [Abstract][Full Text] [Related]
33. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
[No Abstract] [Full Text] [Related]
34. Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody.
Nishiyama H; Tajiri T; Yamabe T; Yasukawa T; Takeda N; Fukumitsu K; Fukuda S; Kanemitsu Y; Uemura T; Ohkubo H; Takemura M; Maeno K; Ito Y; Oguri T; Naniwa T; Niimi A
Intern Med; 2021 Nov; 60(22):3631-3634. PubMed ID: 34092731
[TBL] [Abstract][Full Text] [Related]
35. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis.
Higashitani K; Yoshimi R; Sato Y; Watanabe T; Ihata A
Mod Rheumatol Case Rep; 2022 Jan; 6(1):87-92. PubMed ID: 34473835
[TBL] [Abstract][Full Text] [Related]
36. Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies.
Navarro-Mendoza EP; Tobón GJ
Curr Rheumatol Rep; 2018 Apr; 20(5):23. PubMed ID: 29611001
[TBL] [Abstract][Full Text] [Related]
37. Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis.
Pagnoux C; Berti A
Expert Opin Pharmacother; 2023; 24(11):1269-1281. PubMed ID: 37204027
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
39. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
40. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
